Evaxion announces strategy and business update and third quarter 2026 financial results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evaxion (EVAX) is refocusing its research on cancer vaccines and reported a third-quarter 2026 net loss of $3.5 million. The loss narrowed from $3.7 million in the prior quarter but reversed a $4.6 million profit a year earlier. Quarterly revenue fell to zero from $7.492 million a year earlier. Share sales raised $2.2 million in gross proceeds, and Evaxion expects its cash to last toward the end of 2027.
In advanced melanoma, phase 2 data for personalized vaccine EVX-01 showed 89% vaccine target precision and sustained immune and clinical responses at three years. Evaxion says it is on track to file a phase 1 trial application for EVX-04 by year-end 2026 and plans to advance EVX-05 toward clinical development. Future work on infectious disease programs depends on external partner funding.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.At-the-market share sales raised $2.2 million in gross proceeds; Evaxion expects cash to last toward the end of 2027 9.4% of market cap
- Moderate pointEVX-01 phase 2 data showed sustained T-cell and clinical responses at three years in advanced melanoma
- Minor pointEVX-01 vaccine target precision was 89% in the phase 2 advanced melanoma trial
- Minor point. Forward-looking: it has not happened yet and may not happen.EVX-04 phase 1 trial application is on track for filing before the end of 2026, Evaxion says
- Minor point. Forward-looking: it has not happened yet and may not happen.EVX-05 is slated to advance toward clinical development under Evaxion’s cancer vaccine refocus
7 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.EVX-01 expansion into additional indications is planned through partnerships
- Minor point. Forward-looking: it has not happened yet and may not happen.Cancer vaccine target discovery will continue under Evaxion’s revised research strategy
- Minor pointR&D expenses fell to $2.312 million from $3.092 million year over year in Q3 and to $6.943 million from $7.415 million over nine months
- Minor pointGeneral and administrative expenses fell to $1.361 million from $1.377 million year over year in Q3 and to $4.394 million from $5.295 million over nine months
- Minor pointTotal liabilities fell to $10.523 million at September 30 from $11.369 million at December 31, 2025
- Minor pointEVX-B4 vaccine targets reached a preclinical validation milestone
- Minor point. Forward-looking: it has not happened yet and may not happen.Autoimmune concept validation is planned to support potential future partnerships
Negative
- Moderate pointQ3 net loss of $3.5 million narrowed from $3.7 million in Q2 2026 but reversed a $4.6 million year-earlier profit
- Moderate pointQ3 revenue fell to zero from $7.492 million a year earlier, when Evaxion recorded EVX-B3 licensing revenue; nine-month revenue fell to zero from $7.528 million
- Moderate pointNine-month net loss widened to $10.899 million from $1.789 million a year earlier
- Moderate pointCash and cash equivalents fell to $13.3 million at September 30 from $14.0 million at June 30, 2026, and $23.234 million at December 31, 2025
- Moderate pointTotal equity fell to $8.143 million at September 30 from $17.039 million at December 31, 2025
- Moderate pointAt-the-market issuance of Evaxion shares diluted existing shareholders
- Moderate point. Forward-looking: it has not happened yet and may not happen.Future infectious disease research will proceed only if funded by external partners
4 minor points
- Minor pointOperating results swung to a $3.673 million Q3 loss from a $3.022 million profit a year earlier; the nine-month operating loss widened to $11.338 million from $5.182 million
- Minor pointPer-share results swung to a $0.01 Q3 loss from a $0.01 profit a year earlier; the nine-month loss widened to $0.03 from $0.01, basic and diluted
- Minor pointQ3 net financial expense was $0.1 million, versus $1.3 million in net financial income a year earlier
- Minor pointTotal assets fell to $18.665 million at September 30 from $28.408 million at December 31, 2025
News Explained
The EIB filing concerns possible resale of warrant shares, not an issuer capital raise.
The ATM share sales brought
Separately, the F-1 amendment filed in November concerns only possible resale by the European Investment Bank of shares issuable upon exercise of warrants received in the 2025 debt settlement; the company says it is not conducting a capital raise.
Key Figures
- Vaccine target precision
- 89%
- EVX-01
- Gross ATM proceeds
- $2.2 million
- Raised through the ATM equity program
- Net loss
- $3.5 million
- Q3 2026; compared with a $3.7 million loss in Q2 2026 and $4.6 million profit in Q3 2025
- Cash and cash equivalents
- $13.3 million
- As of September 30, 2026
- Cash runway
- Towards the end of 2027
- Runway extension reported with Q3 2026 results
Previous Earnings Reports
-
Reported a $3.7 million net loss, runway into H2 2027, and pipeline updates.
-
Reported $7.5 million revenue and $4.6 million net income, including EVX-B3 licensing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
neoantigens medical
endogenous retrovirus (erv) medical
ind-enabling studies regulatory
at-the-market (atm) equity program financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
COPENHAGEN, Denmark, November 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, provides strategy and business update and announces third quarter 2026 financial results.
Strategy update
Evaxion is refocusing its strategy to prioritize its immuno-oncology assets and capabilities, fully leveraging AI-Immunology™ in novel cancer target discovery and cancer vaccine development.
The aim is to maximize the value given clinical validation of the platform in personalized cancer vaccines with EVX-01 and the broader opportunity with off-the-shelf cancer vaccines in multiple indications through access to a wider diversity of novel antigens, including but not limited to endogenous retroviruses (ERVs).
Going forward, Evaxion will focus its R&D portfolio by:
- Advancing off-the-shelf cancer vaccines EVX-04 and EVX-05 towards clinical development
- Expanding personalized cancer vaccine EVX-01’s potential in multiple indications via partnerships
- Continuing to identify new cancer vaccine targets for further development by mining novel sources from the dark genome
- Working through partnerships on our preclinical portfolio of infectious disease assets
- Completing validation on the autoimmune concepts we have developed with AI-Immunology™ for future partnerships
As a result of the refocused strategy, Evaxion will make some adjustments to its organization.
“We are refocusing our strategy on the unique capabilities of AI-Immunology™ in discovery and design of novel cancer vaccines. Evaxion’s AI-Immunology™ platform has recently been further validated by stronger clinical and translational datasets from the phase 2 trial with EVX-01 in advanced melanoma at a time when the entire landscape around personalized cancer vaccines has changed more positively. With the ability to also produce off-the-shelf cancer vaccines, we are maintaining strong operational momentum on all of our milestones for the year, tracking towards achieving the last one with the EVX-04 off-the-shelf vaccine clinical trial submission, as we re-focus our efforts towards immuno-oncology”, says Helen Tayton-Martin, CEO of Evaxion.
Business highlights (since last quarterly update)
- Presentation of three-year clinical outcome and immune data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 and additionally new phase 2 biomarker data at SITC 2026
- Announcing the upcoming presentation of new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the ASH 2026 Meeting
- Winning the 2026 International Prix Galien Award for Best digital health solution for AI-Immunology™
- Our cash runway has been extended towards the end of 2027
Conference call and webcast
Evaxion’s executive management will host a conference call and webcast at 8.30am ET/14.30 CET today, presenting the business update and financial results as well as taking questions.
To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.
To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.
Research & Development (R&D) update
Evaxion has a R&D pipeline of innovative vaccine candidates for both cancer and infectious diseases and has recently made progress in both areas.
Most notably, we have presented new phase 2 data for personalized cancer vaccine EVX-01, our most advanced pipeline asset, at both the European Society for Medical Oncology (ESMO) and Society for Immunotherapy of Cancer (SITC) congresses.
Designed with our AI-Immunology™ platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient's immune system to attack the cancer by mounting a targeted response against tumor-specific neoantigens.
EVX-01 is intended for first-line treatment of multiple advanced solid cancer tumors and has, in the phase 2 trial, been evaluated as a treatment of advanced melanoma. The recent data shows an
The very high precision rate is another confirmation that AI-Immunology™ identifies and selects the most therapeutically relevant vaccine targets. Thus, the new data supports both EVX-01 as a promising personalized cancer vaccine and AI-Immunology™ as a validated technology for discovery and design of novel cancer treatments.
Further to the personalized approach, we are leveraging AI-Immunology™ to develop novel off-the-shelf cancer vaccines, including EVX-04 targeting AML. Developed with AI-Immunology™, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.
We are on track to file the application for a phase 1 trial with EVX-04 before the end of the year and continue to advance preclinical IND-enabling studies and expand the data package. We are very much looking forward to presenting new target validation data for EVX-04 at the important American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana, December 12-15, 2026.
Within infectious diseases we have achieved the milestone of designing and preclinically validating antigens to be included in EVX-B4, a novel vaccine candidate for Group A Streptococcus. As per our refocused strategy, we will only conduct future work on our infectious disease programs if funded by external partners and will continue to proactively pursue relevant partnership opportunities.
We have also recently presented AI-Immunology™ derived novel therapeutic concepts for autoimmune diseases. Our future activities in this space will be focused on concept validation for potential future partnerships.
Business development update
We remain active in multiple parallel partnership discussions based on external interest in both AI-Immunology™ and our R&D pipeline based on the strong clinical validation of our platform and as we continue to pursue our strategy of developing novel IO assets and strengthening our platform through strategic partnerships.
We were honored to receive the prestigious International Prix Galien Award for AI-Immunology™ as best digital health solution in October. The award is another strong external validation and recognition of the AI-Immunology™ platform in generating key data confirming the fact that AI-Immunology™ is a platform that delivers meaningful therapeutic product candidates. This is an important distinction with potential business partners.
Third quarter 2026 financial results
We have extended our cash runway towards the end of 2027 through utilization of our At-The-Market (ATM) equity program selling Evaxion shares resulting in gross proceeds of
Earlier in November, we filed an amendment to the registration statement on Form F-1 related to the 2025 debt settlement agreement with The European Investment Bank (EIB) with the US Securities and Exchange Commission.
The registration statement was originally filed in November 2025, as required under the agreement under which EIB converted debt to warrants, and relates solely to the possible resale by EIB of shares issuable upon exercise of those warrants. We are not conducting a capital raise.
The financial results for the third quarter 2026 were in line with expectations with a net loss of
Compared to same period last year where we recorded revenue from out-licensing EVX-B3 to MSD, no revenue has been recorded in Q3 2026, while we have reduced cost in the quarter compared to last year primarily relating to lower personnel expenses and capital market costs, and our net financial expenses reflects normalized financial income and expenses.
Research and development (R&D) expenses were
General and administrative (G&A) expenses were
Net financial expense of
Cash and cash equivalents as of September 30, 2026, were
Total equity amounts to
Evaxion A/S
(Unaudited) Consolidated statement of financial position data
(USD in thousands)
| Sep 30, 2026 | Dec 31, 2025 | |
| Cash and cash equivalents | 13,274 | 23,234 |
| Total assets | 18,665 | 28,408 |
| Total liabilities | 10,523 | 11,369 |
| Share capital | 17,129 | 15,791 |
| Other reserves | 130,301 | 127,492 |
| Accumulated deficit | (139,288) | (126,244) |
| Total equity | 8,143 | 17,039 |
| Total liabilities and equity | 18,665 | 28,408 |
Evaxion A/S
(Unaudited) Consolidated statement of comprehensive loss data
(USD in thousands, except per share data)
| Three Months Ended Sep 30, | Nine Months Ended Sep 30, | |||
| 2026 | 2025 | 2026 | 2025 | |
| Revenue | - | 7,492 | - | 7,528 |
| Research and development | (2,312) | (3,092) | (6,943) | (7,415) |
| General and administrative | (1,361) | (1,377) | (4,394) | (5,295) |
| Operating profit/(loss) | (3,673) | 3,022 | (11,338) | (5,182) |
| Finance income | 152 | 2,690 | 557 | 5,729 |
| Finance expenses | (212) | (1,360) | (730) | (2,988) |
| Net profit/(loss) before tax | (3,732) | 4,352 | (11,511) | (2,442) |
| Income tax benefit | 191 | 265 | 611 | 652 |
| Net profit/(loss) for the period | (3,541) | 4,618 | (10,899) | (1,789) |
| Net loss attributable to shareholders of Evaxion A/S | (3,541) | 4,618 | (10,899) | (1,789) |
| Loss per share – basic and diluted | (0.01) | 0.01 | (0.03) | (0.01) |
| Number of shares used for calculation (basic and diluted) | 431,856,012 | 318,041,649 | 422,013,554 | 289,792,967 |
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering clinical-stage TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. Evaxion harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer. Through partnerships AI-Immunology™ can also be applied in infectious and autoimmune diseases.
With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.
We have developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.